Results 21 to 30 of about 136,011 (340)

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

JAMA Oncology, 2020
Key Points Question Does programmed cell death 1 immune checkpoint inhibition with nivolumab improve overall survival compared with bevacizumab treatment for patients with recurrent glioblastoma?
D. Reardon, A. Brandes, A. Omuro, P. Mulholland, M. Lim, A. Wick, J. Baehring, M. Ahluwalia, P. Roth, O. Bähr, S. Phuphanich, J. Sepúlveda, P. de Souza, S. Sahebjam, M. Carleton, K. Tatsuoka, C. Taitt, R. Zwirtes, J. Sampson, M. Weller   +19 more
semanticscholar   +1 more source

Vascular co‐option and vasculogenic mimicry mediate resistance to antiangiogenic strategies

Cancer Reports, Volume 5, Issue 12, December 2022., 2022
Abstract Background The concept that all the tumors need the formation of new vessels to grow inspired the hypothesis that inhibition of angiogenesis would have led to “cure” cancer. The expectancy that this type of therapy would have avoided the insurgence of resistance was based on the concept that targeting normal vessels, instead of the cancer ...
Francesco Pezzella, Domenico Ribatti
wiley   +1 more source

Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. [PDF]

, 2017
Anti-angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durability. While mechanisms of resistance remain undefined, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the
Aghi, MK, Castro, BA, Chen, W, De Lay, M, Flanigan, P, Hoffman, D, Jahangiri, A, Kohanbash, G, Kuang, R, Mascharak, S, Okada, H, Shrivastav, S, Sidorov, M, Wagner, JR, Yagnik, G   +14 more
core   +1 more source

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source

Bevacizumab for the Treatment of Glioblastoma

Clinical Medicine Insights: Oncology, 2013
Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) is only 14–15 months and less than 10% of patients will survive 5 years after diagnosis. There is no standard treatment in recurrent GBM and OS ranges from 3 to 9 months. GBM is 1 of the most vascularized human tumors
Carlos Mesia, Jordi Bruna, Montserrat Rey, Miguel Gil-Gil   +3 more
openaire   +8 more sources

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study

Cancer Medicine, 2023
Background BAT1706 is a proposed biosimilar of bevacizumab (Avastin®). We aimed to compare the efficacy and safety of BAT1706 with that of EU‐sourced reference bevacizumab (EU‐bevacizumab) in patients with advanced nonsquamous non‐small cell lung cancer (
Likun Chen, Jose David Gomez Rangel, Timucin Cil, Xingya Li, Irfan Cicin, Yihong Shen, Zhihua Liu, Ozgur Ozyilkan, Bondarenko Igor, Jun Chen, Kostiuk Oleksandr, Zhendong Chen, Helong Zhang, Ziyi Fu, Qingfeng Dong, Shuqiang Song, Jin‐Chen Yu, Li Zhang   +17 more
doaj   +1 more source

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

New England Journal of Medicine, 2004
BACKGROUND Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promising preclinical and clinical activity against metastatic colorectal cancer, particularly in combination with chemotherapy. METHODS Of 813 patients
H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar   +14 more
semanticscholar   +1 more source

Bevacizumab in recurrent glioblastoma [PDF]

Translational Cancer Research, 2019
In May 2009, the U.S. Food and Drug Administration granted accelerated approval for the use of bevacizumab in patients with progressive glioblastoma (GBM), the most common malignant primary brain tumor in adults (1). Neovascularization is a morphologic hallmark of GBM, driven in part by vascular endothelial growth factor A (VEGF-A) which is targeted ...
Nina L. Martinez, Jon Glass, Wenyin Shi
openaire   +2 more sources

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Hepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara   +29 more
wiley   +1 more source

EXPERIENCE OF BEVACIZUMAB USE IN PATIENTS WITH INOPERABLE COLORECTAL CANCER IN KIROV REGION

Тазовая хирургия и онкология, 2015
Purpose. To conduct retrospective analysis of treatment results of combined first line therapy of metastatic colorectal cancer with bevacizumab with further bevacizumab maintenance and second line treatment with or without bevacizumab use in Kirov ...
N. Z. Sherman, M. S. Ramazanova, Ye. N. Gopachenko   +2 more
doaj   +1 more source